Get the Stockscreener App
23.51
0.51%
-0.12
After Hours:
23.51
Amphastar Pharmaceuticals Inc stock is traded at $23.51, with a volume of 322.32K.
It is down -0.51% in the last 24 hours and down -16.22% over the past month.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
See More
Previous Close:
$23.63
Open:
$23.69
24h Volume:
322.32K
Relative Volume:
0.64
Market Cap:
$1.09B
Revenue:
$722.68M
Net Income/Loss:
$134.71M
P/E Ratio:
8.8052
EPS:
2.67
Net Cash Flow:
$109.94M
1W Performance:
-11.55%
1M Performance:
-16.22%
6M Performance:
-2.69%
1Y Performance:
-50.58%
1-Day Range:
$23.42
$24.21
1-Week Range:
$23.20
$26.68
52-Week Range:
$20.39
$53.95
Amphastar Pharmaceuticals Inc Stock (AMPH) Company Profile
Name
Amphastar Pharmaceuticals Inc
Sector
Phone
909-980-9484
Address
11570 SIXTH STREET, RANCHO CUCAMONGA, CA
Compare AMPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMPH
Amphastar Pharmaceuticals Inc
|
23.51 | 1.10B | 722.68M | 134.71M | 109.94M | 2.67 |
|
ZTS
Zoetis Inc
|
142.26 | 62.54B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.72 | 43.30B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.08 | 40.08B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.02 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
440.06 | 19.90B | 3.08B | 1.24B | 1.07B | 25.61 |
Amphastar Pharmaceuticals Inc Stock (AMPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Upgrade | Needham | Hold → Buy |
| May-12-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-04-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-22-24 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-24 | Initiated | JP Morgan | Overweight |
| Nov-17-23 | Initiated | BofA Securities | Neutral |
| Jul-25-23 | Resumed | Jefferies | Buy |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Jul-29-22 | Initiated | CapitalOne | Overweight |
| Jan-07-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-08-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-05-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| May-01-20 | Initiated | Northland Capital | Outperform |
| Mar-13-19 | Downgrade | Needham | Buy → Hold |
| Mar-13-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-10-18 | Reiterated | Needham | Buy |
| Mar-13-18 | Reiterated | Needham | Buy |
| Dec-01-17 | Reiterated | Needham | Buy |
| Nov-09-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-27-17 | Reiterated | Needham | Buy |
| Mar-14-17 | Downgrade | Raymond James | Strong Buy → Outperform |
| Aug-09-16 | Reiterated | Needham | Buy |
| May-10-16 | Reiterated | Needham | Buy |
| Feb-19-16 | Initiated | Wells Fargo | Outperform |
| Jun-19-15 | Reiterated | Needham | Buy |
| Jun-03-15 | Initiated | Raymond James | Strong Buy |
| Jul-21-14 | Initiated | Needham | Buy |
View All
Amphastar Pharmaceuticals Inc Stock (AMPH) Latest News
What’s next for Amphastar Pharmaceuticals Inc. stock priceJuly 2025 Movers & Weekly High Return Opportunities - newser.com
Using economic indicators to assess Amphastar Pharmaceuticals Inc. potentialAnalyst Downgrade & Precise Swing Trade Entry Alerts - newser.com
Will Amphastar Pharmaceuticals Inc. stock deliver shareholder valueWeekly Trade Review & Verified Short-Term Plans - newser.com
Does Amphastar Pharmaceuticals Inc. stock trade at a discount to peersQuarterly Market Summary & Free Risk Controlled Daily Trade Plans - newser.com
What drives Amphastar Pharmaceuticals Inc 29A stock priceTrading Volume Trends & Free Short-Term Trading Strategies - earlytimes.in
Align Technology, Envista, Centene, Amphastar Pharmaceuticals, and Oscar Health Shares Plummet, What You Need To Know - TradingView
Will Amphastar Pharmaceuticals Inc. (29A) stock gain from lower interest ratesJuly 2025 Setups & Entry and Exit Point Strategies - newser.com
BofA Cuts Price Target on Amphastar Pharmaceuticals to $31 From $32 - MarketScreener
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs - Benzinga
Can Amphastar Pharmaceuticals Inc. stock attract ESG capital inflowsMarket Volume Report & Daily Entry Point Trade Alerts - newser.com
How to monitor Amphastar Pharmaceuticals Inc. with trend dashboardsQuarterly Risk Review & Safe Capital Growth Trade Ideas - newser.com
Will Amphastar Pharmaceuticals Inc. stock recover after recent dropMarket Volume Summary & Expert Curated Trade Setups - newser.com
Amphastar Pharmaceuticals' (AMPH) Hold (C-) Rating Reaffirmed at Weiss Ratings - MarketBeat
Will Amphastar Pharmaceuticals Inc. (29A) stock return to pre crash levels2025 Volume Leaders & Growth Focused Entry Reports - newser.com
What analysts say about Cochlear Limited OC5 stockIPO Market Watch & Zero-Cost Stock Research by Professionals - earlytimes.in
Momentum divergence signals in Amphastar Pharmaceuticals Inc. chartAnalyst Downgrade & Precise Swing Trade Entry Alerts - newser.com
Why Amphastar Pharmaceuticals Inc. stock is a value investor pickJuly 2025 Patterns & Reliable Momentum Entry Alerts - newser.com
Amphastar Pharmaceuticals to Present at the 2025 Bank of America Health Care Conference - 富途牛牛
Will Amphastar Pharmaceuticals Inc. (29A) stock beat international competitionEarnings Recap Report & Free High Return Stock Watch Alerts - newser.com
Is Amphastar Pharmaceuticals Inc. (29A) stock cheap vs fundamentalsEarnings Trend Report & Expert Approved Momentum Ideas - newser.com
Amphastar Pharmaceuticals (NASDAQ:AMPH) Director Sells 500 Shares - MarketBeat
Amphastar Pharmaceuticals, Inc. (AMPH) Stock Analysis: Exploring a 21.35% Potential Upside - DirectorsTalk Interviews
What analysts say about Amphastar Pharmaceuticals Inc stockPrice Momentum Alerts & Small Entry Cost Portfolio - earlytimes.in
What analysts say about Amphastar Pharmaceuticals Inc 29A stockMarket Sentiment Extremes & Breakout Stock Alerts - Early Times
What drives Amphastar Pharmaceuticals Inc stock priceValue Traps to Avoid & Outstanding Return Stocks - earlytimes.in
CX Institutional Has $6.05 Million Stock Position in Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
CX Institutional Increases Stock Position in Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Analysts Set Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Price Target at $31.60 - MarketBeat
Amphastar Pharmaceuticals Inc Stock (AMPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):